From FDA and Health Canada approvals to joint ventures, here are medtech stories we missed this week but thought were still worth mentioning.
1. FDA clears Joimax Endovapor 2
Joimax announced in an April 26 press release that it has received FDA 510(k) clearance to market its Endovapor 2 Multi-Radio Frequency System. The device generates electricity for monopoly and bipolar cutting and coagulation of tissue structures in surgery. It has programs designed for spinal cord surgery with an interdisciplinary application. It also has 2 monopolar and 2 bipolar sockets with an easy touchpad technology.
2. Health Canada approves Eclipse MicroPen Elite
Eclipse Aesthetics announced that it has received clearance from Health Canada for the Eclipse MicroPen Elite advanced micro-needling device, according to an April 26 press release. The MicroPen Elite is an advanced medical-grade, automated, cordless, high-speed micro-needling device that is designed to improve the appearance of wrinkles, stretch marks, acne scars, skin tone and texture. It can be used on the face, neck, décolleté, arms, hands and more. The MicroPen Elite is a safe alternative to common skin resurfacing tools like lasers and dermal rollers.
3. Theraclion inks Chinese joint venture
Theraclion announced in an April 24 press release that it has signed a joint venture agreement with Inner Mongolia Furui Medical Science Co. Theraclion will own 56% of Theraclion China Co. and 44% of Inner Mongolia Furui Medical Science Co. The joint venture company will be based in Shenzhen, China and will develop the Chinese market for Theraclion’s Echopulse.